<?xml version='1.0' encoding='utf-8'?>
<document id="19695392"><sentence text="Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects."><entity charOffset="45-55" id="DDI-PubMed.19695392.s1.e0" text="rifampicin" /><entity charOffset="83-94" id="DDI-PubMed.19695392.s1.e1" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.19695392.s1.e0" e2="DDI-PubMed.19695392.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19695392.s1.e0" e2="DDI-PubMed.19695392.s1.e1" /></sentence><sentence text="Pravastatin is a potent cholesterol-lowering agent; ~34% of an oral dose of pravastatin is eliminated unchanged through biliary and urinary excretion"><entity charOffset="0-11" id="DDI-PubMed.19695392.s2.e0" text="Pravastatin" /><entity charOffset="24-35" id="DDI-PubMed.19695392.s2.e1" text="cholesterol" /><entity charOffset="76-87" id="DDI-PubMed.19695392.s2.e2" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.19695392.s2.e0" e2="DDI-PubMed.19695392.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19695392.s2.e0" e2="DDI-PubMed.19695392.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19695392.s2.e0" e2="DDI-PubMed.19695392.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19695392.s2.e1" e2="DDI-PubMed.19695392.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19695392.s2.e1" e2="DDI-PubMed.19695392.s2.e2" /></sentence><sentence text=" Rifampicin is an inducer of drug metabolism enzymes, and it affects the activities of transporters involved in pravastatin disposition"><entity charOffset="1-11" id="DDI-PubMed.19695392.s3.e0" text="Rifampicin" /><entity charOffset="112-123" id="DDI-PubMed.19695392.s3.e1" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.19695392.s3.e0" e2="DDI-PubMed.19695392.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19695392.s3.e0" e2="DDI-PubMed.19695392.s3.e1" /></sentence><sentence text=" Drug-drug interaction between rifampicin and pravastatin is possible because of the effects of rifampicin on the activities of drug transporters"><entity charOffset="31-41" id="DDI-PubMed.19695392.s4.e0" text="rifampicin" /><entity charOffset="46-57" id="DDI-PubMed.19695392.s4.e1" text="pravastatin" /><entity charOffset="96-106" id="DDI-PubMed.19695392.s4.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.19695392.s4.e0" e2="DDI-PubMed.19695392.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19695392.s4.e0" e2="DDI-PubMed.19695392.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19695392.s4.e0" e2="DDI-PubMed.19695392.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19695392.s4.e1" e2="DDI-PubMed.19695392.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19695392.s4.e1" e2="DDI-PubMed.19695392.s4.e2" /></sentence><sentence text="" /><sentence text="This study was designed to investigate the effects of a single oral dose of rifampicin on the pharmacokinetics of pravastatin"><entity charOffset="76-86" id="DDI-PubMed.19695392.s6.e0" text="rifampicin" /><entity charOffset="114-125" id="DDI-PubMed.19695392.s6.e1" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.19695392.s6.e0" e2="DDI-PubMed.19695392.s6.e0" /><pair ddi="false" e1="DDI-PubMed.19695392.s6.e0" e2="DDI-PubMed.19695392.s6.e1" /></sentence><sentence text="" /><sentence text="Healthy Chinese male volunteers were recruited for this 2-phase, single-blind, placebo-controlled, crossover study" /><sentence text=" The subjects were randomly divided into 2 groups to receive either rifam-picin or placebo concomitantly with pravastatin"><entity charOffset="110-121" id="DDI-PubMed.19695392.s9.e0" text="pravastatin" /></sentence><sentence text=" All subjects received a 20-mg oral dose of pravastatin on days 1 and 9, separated by an 8-day washout period"><entity charOffset="44-55" id="DDI-PubMed.19695392.s10.e0" text="pravastatin" /></sentence><sentence text=" Subjects in the rifampicin group received a single 600-mg oral dose of rifampicin on day 1 and placebo on day 9; those in the placebo group received placebo on day 1 and a single 600-mg oral dose of rifampicin on day 9"><entity charOffset="17-27" id="DDI-PubMed.19695392.s11.e0" text="rifampicin" /><entity charOffset="72-82" id="DDI-PubMed.19695392.s11.e1" text="rifampicin" /><entity charOffset="200-210" id="DDI-PubMed.19695392.s11.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.19695392.s11.e0" e2="DDI-PubMed.19695392.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19695392.s11.e0" e2="DDI-PubMed.19695392.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19695392.s11.e0" e2="DDI-PubMed.19695392.s11.e2" /><pair ddi="false" e1="DDI-PubMed.19695392.s11.e1" e2="DDI-PubMed.19695392.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19695392.s11.e1" e2="DDI-PubMed.19695392.s11.e2" /></sentence><sentence text=" High-performance liquid chromatography-tandem mass spectrometry was used to determine plasma concentrations of pravastatin for up to 12 hours after administration"><entity charOffset="112-123" id="DDI-PubMed.19695392.s12.e0" text="pravastatin" /></sentence><sentence text="" /><sentence text="Twelve volunteers participated in the study (6 per group)" /><sentence text=" The mean (SD) age of the subjects was 20 (2) years (range, 18-25 years)" /><sentence text=" The mean height of the subjects was 174 (4) cm (range, 168-180 cm), and the mean weight was 69" /><sentence text="2 (3" /><sentence text="7) kg (range, 65-77 kg)" /><sentence text=" The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315"><entity charOffset="41-52" id="DDI-PubMed.19695392.s19.e0" text="pravastatin" /><entity charOffset="97-107" id="DDI-PubMed.19695392.s19.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.19695392.s19.e0" e2="DDI-PubMed.19695392.s19.e0" /><pair ddi="false" e1="DDI-PubMed.19695392.s19.e0" e2="DDI-PubMed.19695392.s19.e1" /></sentence><sentence text="7 [227" /><sentence text="2] and 115" /><sentence text="8 [77" /><sentence text="5] ng " /><sentence text=" mL(-1) [P = 0" /><sentence text="009]); AUC(0-12) (604" /><sentence text="8 [73" /><sentence text="3] and 259" /><sentence text="0 [133" /><sentence text="4] ng " /><sentence text=" h " /><sentence text=" mL(-1) [P &lt; 0" /><sentence text="001]); AUC(0-infinity)) (623" /><sentence text="3 [248" /><sentence text="8] and 275" /><sentence text="1 [58" /><sentence text="5] ng " /><sentence text=" h " /><sentence text=" mL(-1) [P &lt; 0" /><sentence text="001]); and apparent oral clearance (CL/F) (0" /><sentence text="52 [0" /><sentence text="18] and 1" /><sentence text="30 [0" /><sentence text="58] L " /><sentence text=" h(-1) " /><sentence text=" kg(-1) [P &lt; 0" /><sentence text="001])" /><sentence text=" No significant changes in the T(max) or t((1/2)) of pravastatin were observed"><entity charOffset="53-64" id="DDI-PubMed.19695392.s47.e0" text="pravastatin" /></sentence><sentence text=" All subjects tolerated pravastatin well during both phases of the study, with or without coadministration of rifampicin"><entity charOffset="24-35" id="DDI-PubMed.19695392.s48.e0" text="pravastatin" /><entity charOffset="110-120" id="DDI-PubMed.19695392.s48.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.19695392.s48.e0" e2="DDI-PubMed.19695392.s48.e0" /><pair ddi="false" e1="DDI-PubMed.19695392.s48.e0" e2="DDI-PubMed.19695392.s48.e1" /></sentence><sentence text=" None of the subjects withdrew from the study" /><sentence text="" /><sentence text="Coadministration of a single oral dose of rifampicin significantly increased the plasma concentration of pravastatin in this group of healthy Chinese male subjects"><entity charOffset="42-52" id="DDI-PubMed.19695392.s51.e0" text="rifampicin" /><entity charOffset="105-116" id="DDI-PubMed.19695392.s51.e1" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.19695392.s51.e0" e2="DDI-PubMed.19695392.s51.e0" /><pair ddi="false" e1="DDI-PubMed.19695392.s51.e0" e2="DDI-PubMed.19695392.s51.e1" /></sentence><sentence text="" /></document>